A recent Neurology digest,
as sent to subscribers

Study Type: Preclinical animal study (murine model with human brain tissue correlative analysis)

Key Question: Does short-chain fatty acid (SCFA) supplementation modify disease trajectory in drug-resistant epilepsy?

Key Findings:

• SCFA supplementation (acetate, propionate, butyrate mixture) reduced progressive epilepsy phenotype and decreased the progression index 3-fold over 70 days of EEG monitoring, without significantly reducing overall daily seizure frequency
• Treatment reduced seizure clustering, improved cognitive deficits, and restored hippocampal and intestinal histopathological changes
• Metabolomic profiling and human DRE brain tissue analysis supported gut-brain axis dysfunction as a mechanistic contributor to disease progression

Clinical Relevance: For UK neurologists managing drug-resistant epilepsy — a group with very limited disease-modifying options — SCFAs represent a potentially accessible therapeutic avenue warranting clinical translation.

Limitations: Findings are limited to male mice only, restricting generalisability; human tissue analysis is correlative rather than interventional.

Study Type: Prospective cohort study with multiomics analysis

Key Question: What is the local hyperacute innate immune response within the occluded cerebral vasculature during large vessel occlusion stroke?

Key Findings:

• In ischemic blood sampled directly from the occluded MCA in 54 patients (within 4.5 hours of onset), classical monocytes and neutrophils were locally activated compared to paired non-ischemic arterial controls
• IL-1β was identified as a central inflammatory mediator, associated with elevated intravascular ATP and inflammasome priming in monocytes, alongside upregulation of neutrophil-recruiting chemokines CXCL1 and IL-8
• Locally activated neutrophils formed NETs within the ischemic vasculature; postmortem analysis confirmed NET deposition in ischemic brain parenchyma

Clinical Relevance: IL-1β blockade (e.g., anakinra) is already under trial investigation in stroke; these findings provide direct human mechanistic evidence supporting such immunomodulatory approaches in the acute thrombectomy window.

Limitations: Small sample, single-centre design limits generalisability, and causal inference cannot be established from observational sampling alone.

Study Type: Prospective cohort study

Key Question: Does tau PET offer diagnostic advantages over amyloid PET in memory clinic patients with cognitive symptoms?

Key Findings:

• Tau PET showed high sensitivity (97.8%) and specificity (95.4%) for Alzheimer's disease, with substantial agreement with amyloid PET
• In clinically diagnosed non-AD disorders, tau PET produced a significantly higher rate of diagnostic reclassification than amyloid PET alone (p=0.018); adding tau PET after amyloid PET still changed diagnosis in 10% of patients
• Tau PET significantly increased diagnostic confidence from 68.6% to 84.2%, with greater confidence gains than amyloid PET in non-AD conditions

Clinical Relevance: As tau PET becomes more accessible, UK memory clinics managing diagnostically complex cases — particularly suspected non-AD tauopathies — may benefit from tau PET as a complementary tool to amyloid imaging.

Limitations: The exclusively Han Chinese cohort limits direct generalisability to UK memory clinic populations.

Study Type: Narrative review

Key Question: Does cortical hypertrophy represent a genuine and clinically meaningful structural phenomenon in temporal lobe epilepsy, distinct from the established pattern of atrophy?

Key Findings:

• Multiple MRI studies report regions of increased cortical thickness in TLE, though affected regions, patient populations, and analytical methods vary considerably across studies
• Proposed mechanisms include seizure-driven structural remodelling, neuroinflammation/gliosis, compensatory neuroplasticity, and network-level effects
• Methodological variability (surface-based vs. volume-based vs. voxel-based morphometry) substantially influences findings, raising questions about biological validity

Clinical Relevance: Recognising cortical hypertrophy alongside atrophy may refine pre-surgical MRI interpretation and patient selection for epilepsy surgery in NHS tertiary centres.

Limitations: As a narrative review, it is subject to selection bias and does not perform formal meta-analysis; the biological validity of cortical hypertrophy as a true structural finding remains unresolved.

Study Type: GWAS (genome-wide association study) combining in vivo and post-mortem data

Key Question: Can combining amyloid PET and post-mortem histopathological measures of amyloid burden in a large harmonised GWAS identify novel genetic variants underlying Alzheimer's disease neuropathology?

Key Findings:

• Largest brain amyloidosis GWAS to date (n=13,555, European ancestry) confirmed three established AD loci (APOE, BIN1, CR1) and identified a novel chromosome 17 variant (rs35635959; OR=1.18, 95% CI 1.12–1.25) implicating TUBG2, a gene involved in microtubule organisation and synaptic plasticity
• Reduced neuronal TUBG2 expression correlated with increased Aβ burden and AD case status (FDR-corrected p<0.045)
• Modest but significant genetic covariance (0.17) between PET- and histopathology-derived amyloid measures, supporting partial shared genetic architecture across modalities

Clinical Relevance: Identifying TUBG2 as a novel amyloid-associated locus opens potential therapeutic targets beyond APOE, relevant to emerging disease-modifying strategies being evaluated in NHS specialist memory services.

Limitations: The cohort was restricted to European ancestry, limiting generalisability to the ethnically diverse UK population.

Study Type: Multicentre retrospective analysis (international serological cohort)

Key Question: What is the frequency and geographical distribution of MuSK antibodies among seronegative myasthenia gravis (SNMG) patients across international centres?

Key Findings:

• MuSK antibodies detected in 30.8% (143/465) of adult SNMG sera and 40% (17/42) of paediatric cases; absent in AChR-antibody-positive and ocular MG patients
• MuSK-MG demonstrated a striking north–south latitudinal gradient in the Northern Hemisphere (0–47% across European/North American centres), with frequency fitting a Gaussian distribution peaking at approximately 40°N latitude
• MuSK-positive patients showed greater bulbar predominance, clinical severity, and treatment requirements, though responded to more aggressive immunotherapy

Clinical Relevance: UK neurologists should be aware that MuSK-MG frequency may be relatively low at northern latitudes, with implications for diagnostic probability estimation in SNMG patients and broader interest in latitude-dependent IgG4-mediated neurological disease.

Limitations: Centre selection bias and variable cohort sizes, particularly limited data from Southern Hemisphere and Asian centres, constrain generalisability of the latitudinal model.

Study Type: Narrative review

Key Question: What is the relationship between epilepsy, sleep disorders, and aggression — and how does historical stigma distort contemporary clinical and forensic understanding?

Key Findings:

• Ictal aggression is rare, typically undirected, and seldom constitutes true violence; seizure- and parasomnia-related aggression carry significant risk of misclassification in forensic settings
• Neural substrates of aggression in both epilepsy and disorders of arousal show overlapping networks, evidenced by intracerebral/intracranial EEG data, but with distinguishable features relevant to differential diagnosis
• The "epileptic criminal personality" concept, originating in 19th-century psychiatry, continues to fuel stigma with measurable negative impact on quality of life

Clinical Relevance: UK neurologists and forensic clinicians assessing patients with seizure- or sleep-related violent episodes need robust frameworks to distinguish ictal from parasomnia-related aggression, given medicolegal consequences and persisting social stigma.

Limitations: As a narrative rather than systematic review, study selection is partially subjective, increasing risk of bias in conclusions.

Study Type: Preclinical mechanistic study (mouse model)

Key Question: Does a parabrachial nucleus (PBN) CGRP-neuron → central amygdala (CeA) circuit mediate trigeminal V1-specific migraine-like pain?

Key Findings:

• Chemogenetic activation of PBN CGRP (Calca) neurons alone was sufficient to induce periorbital allodynia, photophobia, and reduced rearing in naïve mice
• Silencing PBN Calca neurons (via Gi-DREADD or tetanus toxin) suppressed allodynia triggered by four distinct migraine models (dural inflammatory mediators, CGRP, PACAP, nitroglycerin)
• CRISPR knockout of CeA CGRP receptor component Ramp1 abolished migraine-like symptoms, confirming PBN→CeA CGRP signalling as the critical relay; this pathway was dispensable for non-V1 or extracranial nociception

Clinical Relevance: This identifies a discrete central circuit potentially explaining why anti-CGRP therapies are effective in migraine, and highlights PBN→CeA signalling as a tractable target for novel drug development.

Limitations: Findings are in mice only; translational validity to human migraine pathophysiology remains unestablished.